Mr. Robert Andrade reports

FENNEC PHARMACEUTICALS TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS ON MAY 11, 2023

Fennec Pharmaceuticals Inc. will release its first quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, May 11, 2023. Management will host a conference call and webcast that day to discuss the company's financial and business results.

Conference call and webcast details

Date: Thursday, May 11, 2023

Time: 8:30 a.m. Eastern Time

To access the conference call, please register on-line. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto the Fennec website and proceed to the news and events/event calendar page under the investors and media heading. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on Fennec's website for 30 days.

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of Pedmark to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, Pedmark received Food and Drug Administration approval in September, 2022, and has received orphan drug designation in the United States. Fennec has a licence agreement with Oregon Health and Science University (OHSU) for exclusive worldwide licence rights to intellectual property directed to sodium thiosulphate and its use for chemoprotection, including the reduction of risk of ototoxicity induced by platinum chemotherapy, in humans.